This article highlights the growing trend of 'AI as a Service' (AIaaS) within the healthcare and life sciences sector, with EDETEK launching its Ensemble AI Managed Services to streamline AI adoption and accelerate clinical development. This service, which involves 'orchestrated AI,' suggests a move toward more integrated and managed AI solutions to drive measurable improvements in clinical trials and pharmaceutical research.
In healthcare & life sciences, the AI service provided by EDETEK aims to reduce the cost and time associated with clinical trials. This can be achieved by improving patient selection, predicting outcomes, and optimizing trial design. Positive outcomes can significantly increase the potential revenue and strategic position of pharmaceutical companies with faster FDA approval cycles. This also impacts risk management as AI systems will need to be validated to prove trustworthy predictions
Operational impact: This allows pharmaceutical companies and research institutions to leverage AI without the need for building in-house expertise. It streamlines AI implementation, enabling faster data analysis, improved patient selection for trials, and quicker identification of potential drug candidates. This potentially enables faster iteration and development cycles overall.